Cargando…
If skin is a potential host of SARS-CoV-2, IL-17 antibody could reduce the risk of COVID-19
[Figure: see text]
Autores principales: | Xu, Qiannan, Chen, Lihong, Li, Xia, Zheng, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642734/ https://www.ncbi.nlm.nih.gov/pubmed/33159988 http://dx.doi.org/10.1016/j.jaad.2020.10.084 |
Ejemplares similares
-
Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?
por: Parodi, Aurora, et al.
Publicado: (2020) -
Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”
por: Wan, Marilyn T., et al.
Publicado: (2020) -
Strategies to prevent SARS-CoV-2 transmission during dermatologic head and neck surgery
por: Do, Mytrang H., et al.
Publicado: (2020) -
Comment on “An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology”
por: Speeckaert, Reinhart, et al.
Publicado: (2021) -
The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities
por: Bakhtiar, Mina, et al.
Publicado: (2020)